A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration

Clinical Trial ID NCT00950638

Rank	Title	Journal	Year	PubWeight™‹?›
1	Immunology of age-related macular degeneration.	Nat Rev Immunol	2013	2.14
2	STEC-HUS, atypical HUS and TTP are all diseases of complement activation.	Nat Rev Nephrol	2012	1.89
3	The significance of the complement system for the pathogenesis of age-related macular degeneration - current evidence and translation into clinical application.	Graefes Arch Clin Exp Ophthalmol	2010	1.12
4	Applying complement therapeutics to rare diseases.	Clin Immunol	2015	0.87
5	Role of Factor H and Related Proteins in Regulating Complement Activation in the Macula, and Relevance to Age-Related Macular Degeneration.	J Clin Med	2015	0.83
6	Current therapeutic developments in atrophic age-related macular degeneration.	Br J Ophthalmol	2015	0.83
7	Recent developments in the management of dry age-related macular degeneration.	Clin Ophthalmol	2015	0.81
8	Present and possible therapies for age-related macular degeneration.	ISRN Ophthalmol	2014	0.79
9	Aptamers and their potential to selectively target aspects of EGF, Wnt/β-catenin and TGFβ-smad family signaling.	Int J Mol Sci	2013	0.78
10	Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers.	Int J Mol Sci	2016	0.78
11	Dry age-related macular degeneration: A currently unmet clinical need.	Intractable Rare Dis Res	2012	0.78
12	Targeting the complement system for the management of retinal inflammatory and degenerative diseases.	Eur J Pharmacol	2016	0.78